BCL2 and metabolic dysfunction-associated steatotic liver disease: This led us to hypothesize that targeted overexpression of the Bcl2 gene in adipocytes could prevent adipocyte death, reduce lipid redistribution to hepatocytes, and ameliorate MASLD progression.